GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Current Ratio

Histogen (Histogen) Current Ratio

: 4.05 (As of Sep. 2023)
View and export this data going back to 2020. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Histogen's current ratio for the quarter that ended in Sep. 2023 was 4.05.

Histogen has a current ratio of 4.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Histogen's Current Ratio or its related term are showing as below:

HSTO' s Current Ratio Range Over the Past 10 Years
Min: 1.78   Med: 8.54   Max: 13.22
Current: 4.05

During the past 4 years, Histogen's highest Current Ratio was 13.22. The lowest was 1.78. And the median was 8.54.

HSTO's Current Ratio is ranked better than
52.57% of 1554 companies
in the Biotechnology industry
Industry Median: 3.795 vs HSTO: 4.05

Histogen Current Ratio Historical Data

The historical data trend for Histogen's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Current Ratio
1.78 3.02 9.27 10.90

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.69 10.90 7.92 8.54 4.05

Competitive Comparison

For the Biotechnology subindustry, Histogen's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Histogen Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Histogen's Current Ratio distribution charts can be found below:

* The bar in red indicates where Histogen's Current Ratio falls into.



Histogen Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Histogen's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=13.456/1.234
=10.90

Histogen's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=5.455/1.348
=4.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Histogen  (OTCPK:HSTO) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Histogen Current Ratio Related Terms

Thank you for viewing the detailed overview of Histogen's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Histogen (Histogen) Business Description

Traded in Other Exchanges
N/A
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Executives
Joyce Reyes officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann director C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson officer: See Remarks 9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson director, 10 percent owner C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton officer: See Remarks C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang director 12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich officer: See Remarks C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall officer: EVP, COO & CFO C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127

Histogen (Histogen) Headlines

From GuruFocus

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-01-2022

Histogen Announces Closing of $4.75 Million Private Placement

By GuruFocusNews GuruFocusNews 03-25-2022

Histogen Announces 1-for-20 Reverse Stock Split

By PurpleRose PurpleRose 07-11-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-21-2022

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-26-2022

Histogen Announces $4.75 Million Private Placement

By GuruFocusNews GuruFocusNews 03-23-2022